公开(公告)号：JPH10251146A

公开(公告)日：1998-09-22

申请号：JP5601997

申请日：1997-03-11

Applicant: TORAY INDUSTRIES

Inventor： OKAMOTO SUSUMU ,  SHIGA MASAHARU ,  MIYATA YASUSHI ,  KUWABARA YUJI ,  AOKI SHIGERU ,  KURUMAYA HAJIME

IPC: C07D307/93 ,  A61K31/34 ,  A61K31/343 ,  A61K38/28 ,  A61K45/00 ,  A61P25/00

Abstract: PROBLEM TO BE SOLVED: To allow recovery of lowered functional of motor and sensory nerves in patients suffering from diabetic neuropathy, by using beraprost in combination with a medicine for diabetes. SOLUTION: Treatment of the diabetic neuropathy, especially one accompanied by lowering in nervous conduction speed, is performed by using (A) beraprost in combination with (B) a medicine for diabetes. As the component B, an insulin-containing preparation or a medicine for diabetes for oral use specifically, a preparation containing gliclazide, tolbutamide, chlorpramide, acetohexamide, or gliclopyramide can be used. In principle, it is preferable that both usage and dose of the components A and B are in compliance with the case of their single use.

公开(公告)号：JPH05178756A

公开(公告)日：1993-07-20

申请号：JP34518991

申请日：1991-12-26

Applicant: TORAY INDUSTRIES

Inventor： IDA NOBUTAKA ,  OKAMOTO SUSUMU ,  OKANO KIYOSHI ,  SATO YUICHIRO ,  NARUTO MASANOBU

IPC: A61K38/00 ,  A61P1/16

Abstract: PURPOSE:To obtain a preventing and therapeutic agent for hepatopathy containing interleukin 6 and/or interleukin 11 as an active ingredient. CONSTITUTION:The objective preventing and therapeutic agent is obtained by including interleukin 6 and/or interleukin 11 as a principal ingredient. This interleukin 6 or 11 or both are obtained by culturing a cell derived from a human. This agent is administered by intervenous, subcutaneous or intramuscular injection, intravenous instillation or local infusion or transmucosal administration such as peroral, percutaneous, transpulmonary or enteral administration or the percutaneous administration. The dose is 0.0001-300mug per day and kg body weight. This agent is excellent in function to lower the glutamic-oxaloacetic transaminase(GOT) value and the glutamic-pyruvic transaminase(GPT) value raised by various hepatopathies and useful for the hepatopathies such as viral hepatitis, bacterial or parasitic infectious hepatitis, hepatopathies caused by autoimmune diseases, alcoholic hepatopathies, hepatopathies caused by medicines or poisonous substances, hepatoma or ischemic hepatopathies caused by hepatic transplantation, surgical operation or cardiac infarction.

公开(公告)号：JPH05155779A

公开(公告)日：1993-06-22

申请号：JP1544892

申请日：1992-01-30

Applicant: TORAY INDUSTRIES

Inventor： YOSHIZAWA KENICHI ,  MIWA TAKASHI ,  NARUTO MASANOBU ,  IDA NOBUTAKA ,  OKAMOTO SUSUMU

IPC: A61K38/00 ,  A61P9/00 ,  A61P39/02

Abstract: PURPOSE:To obtain the subject preventing and therapeutic agent, containing interleukin 6 as an active ingredient and having the activity of efficiently treating and preventing bacterial toxic shock. CONSTITUTION:The objective preventing and therapeutic agent is obtained by adding an additive (preferably human blood serum albumin, gelatin, etc.) to interleukin-6(IL-6) prepared by culturing preferably a human cell (e.g. a fibroblast or an endothelial cell) capable of producing the IL-6 as a principal ingredient for stabilization. Furthermore, this agent is used in an amount of 0.0001-10000mug (preferably 0.001-1000mug) daily per kg body weight as an effective dose.